Discussion of preliminary results from an ongoing phase 1 clinical trial studying the safety and efficacy of novel BCL2 inhibitor BGB-11417 alone and in combination with the next-generation BTK inhibitor zanubrutinib.
In this study presented at the American Society of Hematology Annual Meeting and Exhibition (ASH 2021), the authors compared the experience in 5 different age groups on the amount of information provided, how well the information was understood, and topics on which patients and caregivers needed more information.
Join CLL Society and PeerView Institute to learn updates on the latest CLL data from a panel of experts including Drs. Anthony Mato, Nicole Lamanna, Matthew Davids, and Catherine Coombs and gain their insight into the practicalities of therapeutic planning, including safety considerations associated with BTKi, PI3Ki, BCL-2i, and
Our own Dr. Brian Koffman presented alongside Drs. Nitin Jain and Joanna Rhodes at this Cure event. Learn about the disproportionate impact that the COVID-19 pandemic has on immunocompromised patients with chronic lymphocytic leukemia (CLL) and hear potential solutions from leading CLL experts.